JMB2403 / Shanghai Jeyou Pharmaceutical - LARVOL DELTA

JMB2403, a potential best-in-class PD-1-dependent IL2Rβγ-targeting tri-specific antibody for safe and potent immunotherapy (AACR 2026) - "In an A375 (melanoma) xenograft model, JMB2403 (4 mg/kg, i.p., twice weekly) exhibited superior anti-tumor efficacy (complete regression in 7 out of 8 animals) than its parental PD-1 antibody as well as pembrolizumab. In summary, JMB2403 can induce cis-activation of PD-1+ T cells and display superior anti-tumor efficacy with good tolerability. To our knowledge, this is the first tri-specific antibody of its kind that targets specifically IL2/15 receptor signaling subunits."

Trispecific • Lung Cancer • Melanoma • Oncology • Solid Tumor • CD8 • IL2RA • STAT5